Gene · 7423
Papers4,111
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 4,111
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. | Pharmaceuticals (Basel) | 2023 | 37631054 | PubTator, text mining | PubMed |
| Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment. | Int J Mol Sci | 2023 | 37629185 | PubTator, text mining | PubMed |
| Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy. | Cancers (Basel) | 2023 | 37627044 | PubTator, text mining | PubMed |
| Immunomorphogenesis in Degenerative Disc Disease: The Role of Proinflammatory Cytokines and Angiogenesis Factors. | Biomedicines | 2023 | 37626681 | PubTator, text mining | PubMed |
| The anoikis-related gene signature predicts survival accurately in colon adenocarcinoma. | Sci Rep | 2023 | 37626132 | PubTator, text mining | PubMed |
| Beyond Angiogenesis: The Multitasking Approach of the First PEGylated Vascular Endothelial Growth Factor (CdtVEGF) from Brazilian Rattlesnake Venom. | Toxins (Basel) | 2023 | 37624240 | PubTator, text mining | PubMed |
| Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications. | Curr Issues Mol Biol | 2023 | 37623239 | PubTator, text mining | PubMed |
| Progress of research on molecular targeted therapies for colorectal cancer. | Front Pharmacol | 2023 | 37614311 | PubTator, text mining | PubMed |
| Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib. | Thorac Cancer | 2023 | 37605832 | PubTator, text mining | PubMed |
| In vitro cross-talk between metastasis-competent circulating tumor cells and platelets in colon cancer: a malicious association during the harsh journey in the blood. | Front Cell Dev Biol | 2023 | 37601099 | PubTator, text mining | PubMed |
| Pan-cancer analysis of Krüppel-like factor 3 and its carcinogenesis in pancreatic cancer. | Front Immunol | 2023 | 37600783 | PubTator, text mining | PubMed |
| Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review). | Int J Mol Med | 2023 | 37594116 | PubTator, text mining | PubMed |
| Transition metals in angiogenesis - A narrative review. | Mater Today Bio | 2023 | 37593220 | PubTator, text mining | PubMed |
| VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway. | Signal Transduct Target Ther | 2023 | 37591843 | PubTator, text mining | PubMed |
| Modelling host- Trypanosoma brucei gambiense interactions in vitro using human induced pluripotent stem cell-derived cortical brain organoids. | F1000Res | 2023 | 37588058 | PubTator, text mining | PubMed |
| Overexpression of CD99 is associated with tumor adaptiveness and indicates the tumor recurrence and therapeutic responses in gliomas. | Transl Oncol | 2023 | 37579711 | PubTator, text mining | PubMed |
| Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment. | Front Oncol | 2023 | 37576892 | PubTator, text mining | PubMed |
| Darovasertib, a novel treatment for metastatic uveal melanoma. | Front Pharmacol | 2023 | 37576814 | PubTator, text mining | PubMed |
| Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer. | Cancer Res Commun | 2023 | 37575280 | PubTator, text mining | PubMed |
| Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration. | Nutrients | 2023 | 37571296 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7423/papers?page=17